Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000929638-25-002878
Filing Date
2025-08-04
Accepted
2025-08-04 18:21:26
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 12341
  Complete submission text file 0000929638-25-002878.txt   14343
Mailing Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247
Business Address 3060 PEGASUS PARK DRIVE BUILDING 6 DALLAS TX 75247 (310) 618-6994
Forte Biosciences, Inc. (Subject) CIK: 0001419041 (see all company filings)

EIN.: 261243872 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-89959 | Film No.: 251182047
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address SUITES 818-822, 8/F, BANK OF AMERICA TOWER, 12 HARCOURT ROAD, HONG KONG K3 XXXXX
Business Address SUITES 818-822, 8/F, BANK OF AMERICA TOWER, 12 HARCOURT ROAD, HONG KONG K3 XXXXX 852-3983-6800
TYBOURNE CAPITAL MANAGEMENT (HK) LTD (Filed by) CIK: 0001553936 (see all company filings)

EIN.: 000000000 | State of Incorp.: K3 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A